Unlock the Editor’s Digest for absolutely free

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly publication.

Shares in Novavax a lot more than doubled in pre-sector trading right after Sanofi struck a licensing deal really worth up to $1.2bn to commercialise the having difficulties Covid-19 vaccine maker’s coronavirus jab and use the know-how to establish its individual mixed shot with flu.

Novavax shares had been up 130 per cent in advance of Wall Street’s opening bell on Friday to $10.32 following the announcement, which led the US biotech to clear away its “going concern” see that brought about inventory to tank. At one particular stage, the company’s share cost experienced far more than tripled, topping $14 for the to start with time due to the fact December 2022.

The partnership strengthens Sanofi, a person of the world’s biggest vaccine makers by product sales, in the publish-pandemic Covid-19 jab industry, in which pharmaceutical teams are significantly centered on put together pictures towards two or more infectious illnesses.

Beneath the arrangement, Paris-primarily based Sanofi would lead the income push of Novavax’s Covid-19 jab from following year in most international locations throughout the world and have the legal rights to mix the US biotech’s protein-based mostly vaccine engineering with its flu pictures and other infectious disorder jabs, the businesses mentioned on Friday.

Novavax will acquire an upfront payment of $500mn in dollars and an equity financial commitment, and will stand to acquire the remaining $700mn upon the completion of particular regulatory and progress milestones.

Sanofi will just take a approximately 5 for every cent stake in Novavax. Novavax will also benefit from a double-digit percentage of royalties from the gross sales of its Covid jab as nicely as any put together shot making use of its technology, but Sanofi will take the the greater part of revenues.

“We’re fired up by the prospect of combining Novavax’s adjuvanted Covid-19 vaccine that has demonstrated large efficacy and favourable tolerability, with our abundant portfolio of differentiated flu vaccines that have shown top-quality defense against flu and its serious troubles,” said Jean-François Toussaint, who heads Sanofi’s vaccine investigation and development.

Touissant claimed the mixed shot would supply sufferers “enhanced comfort and security against two serious respiratory viruses”. Sanofi had a Covid-19 booster vaccine accredited by the European Medicines Company in 2022 but it has struggled to make a dent in the sector.

The licensing settlement caps a tumultuous period of time for Novavax, whose current market benefit boomed to much more than $40bn at the top of the pandemic, propelled by trader excitement in excess of its Covid shot. But it has because experienced most of its value wiped out.

The vaccine maker has undertaken a $1.1bn charge-reducing drive in the earlier yr to stave off a feasible personal bankruptcy and has faced force from an activist trader for a board shake-up.

Novavax suffered from a sequence of mis-techniques with the start of its Covid-19 vaccine, which was late to marketplace since of a sluggish approval system. It then confronted collapsing demand as governments withdrew from procurement deals.

Novavax’s vaccine, a far more classic protein-based mostly formulation combined with an adjuvant to enhance its efficiency, has been pitched to sufferers as a counterpoint to mRNA jabs from BioNTech/Pfizer and Moderna that have inspired vaccine scepticism above exceptional side-outcomes. But gross sales have lagged.

“Novavax is now in a more powerful situation to refocus our endeavours on leveraging our technological know-how system and novel adjuvant,” reported John Jacobs, Novavax main executive.

Novavax will nonetheless be permitted to push ahead with development of its mixed Covid-flu shot, which is established to enter late-phase trials in the next 50 % of this year.